Eurocine Vaccines prepares to evaluate two more vaccine candidates
As part of its portfolio strategy, Eurocine Vaccines is actively searching for new vaccine candidates to expand the portfolio. Of the currently ongoing discussions with different organizations, two have progressed to a point where experimental evaluations will be the next step.
Eurocine Vaccines´ strategy is based on developing a broad portfolio of vaccine candidates in different phases, giving more innovations the opportunity to reach the market for the benefit of humanity. At the same time, investors are offered risk diversification with greater future leverage.
Eurocine Vaccines is currently in discussions regarding two potential new vaccine candidates, approaching a point where material transfer will be possible, enabling Eurocine Vaccines to conduct confirmatory preclinical studies to verify expected results – an evaluation that is essential prior to adding any new candidate to the portfolio. Such studies are now prepared, one for each candidate.
“It is exciting times for us when both protein and mRNA-based vaccines may be combined in our portfolio, proving our thorough and broad experience”, says Dr Hans Arwidsson, CEO Eurocine Vaccines.
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines AB
+46 70 634 0171
Eurocine Vaccines is a development company in the highly intense vaccine area, bridging the gap between innovation and market.
Through its portfolio strategy, innovative vaccine candidates are given the opportunity to reach the market quicker, while investors are offered risk diversification with a big future leverage. These candidates are later licensed to partners for commercialization.
The company is in the possession of its own technology platform, Endocine™, which has been tested in four extensive clinical studies with over 400 subjects.
Listed at Spotlight Stock Market, XSAT, Eurocine Vaccines, EUCI, today operates at the heart of the bio-scientific cluster of Karolinska Institutet, Solna, Sweden and has attracted several internationally merited vaccine specialists to its board.
KOMMUNIKÉ FRÅN ÅRSTÄMMA 2021 I QUIAPEG PHARMACEUTICALS HOLDING AB
Följande huvudsakliga beslut fattades på årsstämman.Fastställande av resultat- och balansräkning samt resultatdispositionÅrsstämman fastställde resultat- och balansräkningen för räkenskapsåret 2020 i enlighet med avgiven årsredovisning.Årsstämman godkände styrelsens förslag avseende resultatdisposit...
DBP International AB: The CTA for SI-053 has been sent - the tenth and the last milestone for the clinical trial of SI-053 has been completed
Double Bond Pharmaceutical reports that the CTA for SI-053 has been submitted to the competent National Regulatory Authorities, including the Ethics Committee. The process was carried out by DBP in cooperation with a company specializing in managing clinical trials located in the EU, on behalf of ph...
DBP International AB: CTA för SI-053 har skickats - den tionde och sista milstolpen för den kliniska prövningen av SI-053 har slutförts
Double Bond Pharmaceutical rapporterar att CTA för SI-053 har skickats till behöriga, nationella regleringsmyndigheter, inklusive etikkommittén. Processen genomfördes av DBP i samarbete med ett företag som är specialiserat på att hantera kliniska prövningar...